BASF Pharmaceutical Solutions Presented at CPHI Worldwide in Frankfurt, Germany

BASF representatives will be participating at CPHI Worldwide, the world’s largest pharmaceutical trade fair scheduled to take place in Frankfurt, Germany (hall 3.1, booth 31E19), 22–24 October 2013, to discuss the company's intelligent end-to-end solutions and high-quality products such as APIs, excipients, catalysts, reagents and inorganic specialties.

Omega-3 Solutions for all Requirements

By acquiring Pronova BioPharma, BASF has achieved a leading position in the global market for omega-3 fatty acids. This transaction complements the acquisition of Equateq, now BASF Pharma (Callanish), in May 2012 and expands BASF’s omega-3 portfolio. BASF’s offering now covers the full range of medium- to highly concentrated omega-3 fatty acids for use in nutrition, dietary supplements and pharmaceuticals.

BASF’s highly concentrated and extremely pure omega-3 fatty acids are used as APIs to treat cardiovascular diseases such as post-myocardial infarction and hyperlipidemia/ hypertriglyceridemia; they are also used in nutritional applications.

Generic APIs to Rely on

Omega-3 fatty acids are a recent major enhancement to BASF’s diverse API portfolio that has gained the trust of the pharmaceutical industry over many decades. BASF is a worldwide leading supplier of ibuprofen, caffeine, pseudoephedrine, theophylline and phenylephrine among many other generic active pharmaceutical ingredients.

Exceptional Bioavailability Through Innovative Excipients

The challenge for pharmaceutical companies to enhance the solubility of active ingredients can only be tackled with the right solubilisers and process technologies. BASF provides solutions for such solubilisation challenges to support customers’ success, as proven for instance by the high-throughput screening robot Solu-HTS that speeds up the selection of the best solubilizer or combination for poorly soluble APIs.

BASF’s portfolio includes exceptional solubilizing agents such as the award-winning Soluplus and the Kolliphor and Kollidon ranges. These products can be used in standard production processes, as well as with innovative process technologies such as hot-melt extrusion (HME) for optimal results.

Skin Delivery Excellence

When it comes to topical formulations, every single ingredient counts; pharmaceutical quality is ideally rounded off with the right sensory experience. BASF is committed to best-in-class quality across the topical ingredients spectrum, whether emulsifiers, gel formers, consistency factors, solvents, actives or emollients.

Custom Synthesis Services to Satisfy Unique Manufacturing Requirements

BASF is a leading provider of custom APIs and intermediates for the pharmaceutical industry. Partnering with BASF gives customers the opportunity to establish long-term security of supply by relying on BASF’s proven track record in the pharmaceutical industry. Customers benefit from BASF’s manufacturing expertise and flexibility and gain access to its global research and development network, where value-added technologies are constantly emerging. Through its value proposition, BASF Custom Synthesis offers innovative solutions that help to simplify production processes and optimize costs.

High-Quality Solvents and Reagents to Meet Customers’ Needs

BASF develops tailor-made products such as the recently launched Tetrakis (dimethylamino) diboron DMA4B2, thus meeting the very specific needs for the production of the API. The new boronation reagent for Suzuki coupling reactions offers full flexibility and works with a broad range of different solvents and catalysts. Moreover, it enables borylations to be carried out at higher concentrations and even in solvent-free reactions.

With its N-Methylpyrrolidone Life Science (NMP Life Science) BASF also offers another high quality product that provides an innovative solution for the pharmaceutical industry. Specially designed for use in pharmaceutical peptide synthesis and similar applications where high solvent purity is an advantage, NMP Life Science improves the process efficiency. Due to its low amine content of below 1 part per million (ppm) and low water content of below 0.03 percent, the yield in solid-phase peptide synthesis can be increased by up to 15% compared with standard grade NMP.

Environmentally Friendly Catalysts

BASF Catalysts will be starting a production line for precious metal-based fine chemical catalysts at the company’s manufacturing site in Mangalore, India in October 2013. This marks BASF’s first manufacturing operation for chemical catalysts in Asia Pacific. With this new manufacturing line, BASF enhances its proximity to customers in the Asia Pacific region and expands its offerings to meet the needs of local pharmaceutical and fine chemical producers.

Among the technologies used in Mangalore for the production of precious-metal based catalysts will also be BASF's innovative NanoSelect platform technology. The NanoSelect technology already resulted in the development of the lead-free palladium (Pd) catalysts as a replacement for Lindlar catalysts. More recently highly efficient platinum-based catalysts were also developed which show, for example, high nitro group hydrogenation activity with lower platinum requirements. In addition, BASF's NanoSelect platform technology has enabled the production of modified platinum catalysts with good selectivity in halo nitro aromatic hydrogenation reactions.